Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 10, 2011

View Archived Issues

TSRL discloses preclinical data on neuraminidase inhibitor prodrugs

GSK FLAP inhibitor attenuates allergen-induced asthma responses in phase II trials

MRI technique may aid in differentiating Gulf War illness variants

Study identifies SNPs associated with severity of A/H1N1/2009 influenza in children

Protalix Biotherapeutics patents novel cross-linked multimeric proteins for Gaucher's disease

Promising phase III data disclosed on VX-770 in CF

AXL-1717 benefits patients with advanced-stage NSCLC in phase I trial

Scientists in Taiwan identify miRNA signature associated with incidence of oral cancer

Amgen discloses novel series of beta-secretase 1 inhibitors

Novel prostanoid DP1 receptor antagonists synthesized by Sanofi

New TRPA1 channel antagonists presented by Glenmark Pharmaceuticals

Novel agents for bacterial infections claimed

New SSAO inhibitors described by Proximagen

FDA approves Merck & Co.'s Juvisync

Epix Pharmaceuticals and Amgen S1P1 program assets to be offered for sale

BAY-1017858 shows promise in vitro and in vivo

Abbott enrolls first patients in EXCEL trial evaluating Xience everolimus-eluting stents

FDA and Starpharma agree on phase III program for VivaGel

Victoza launched in China

Trimel Pharmaceuticals provides update on phase II Vibro-Tactile Stimulation trial

Hybrigenics and Servier sign license and collaboration agreement covering multiple fields

Adherex to discuss development of sodium thiosulfate with FDA advisory committee

Biotron provides results from preliminary analysis of BIT-225 study

Paladin Labs completes Labopharm acquisition

Combivent Respimat approved in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...